Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
Details
Serval ID
serval:BIB_1BCA2AEDCDC7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
Journal
AIDS
ISSN
0269-9370 (Print)
Publication state
Published
Issued date
10/2000
Volume
14
Number
15
Pages
2257-63
Notes
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Oct 20
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Oct 20
Abstract
OBJECTIVE: When to start highly active antiretroviral therapy (HAART) in asymptomatic chronically HIV-1-infected subjects with CD4 cell counts of 300 x 10(6)-500 x 10(6)/l is debated extensively. Retrospective analyses of virological and immunological responses following HAART have been evaluated in both blood and lymph nodes according to pre-treatment levels of CD4 cells either above or below 500 x 10(6)/l. DESIGN: Open-label, observational, non-randomized, prospective study. SETTING: Outpatients attending the Centre of Clinical Investigation in Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. PARTICIPANTS: Fifty-four HIV-1-infected antiretroviral-naive subjects with CD4 cell count > or = 250 x 10(6)/l and plasma viraemia > or = 5000 copies/ml who had been treated with HAART for at least 48 weeks. Controls were 49 HIV-negative subjects. INTERVENTIONS: All patients received abacavir, nelfinavir, saquinavir soft gel capsules, and amprenavir in varying combinations for 72 weeks. MAIN OUTCOME MEASURES: The extent of immune reconstitution following HAART in 43 and 11 subjects with either more or fewer than 500 x 10(6) CD4 cells/l at baseline was evaluated in blood and lymph node, and compared with immunological measures observed in 49 HIV-negative controls. RESULTS: After 48 weeks of therapy, plasma viraemia was suppressed effectively in both groups of patients. Normalization of both CD4 cell count in blood, divided equally between memory and naive cells, and percentage of CD4 cells in lymph nodes occurred in the two groups. Consistently, the net increase over baseline in CD4 cell count and in memory and naive CD4 subsets was greater in patients with fewer than 500 x 10(6) CD4 cells/l at baseline. Recovery of HIV-specific responses was similar in the two groups. CONCLUSIONS: This study suggests that virological and immunological responses are comparable in asymptomatic therapy-naive HIV-1-infected subjects with CD4 cell counts above or below 500 x 10(6)/l.
Keywords
Adult
Anti-HIV Agents/*therapeutic use
Antigens, Fungal/immunology
Antigens, Viral/immunology
*Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Candida albicans/immunology
Carbamates
Chronic Disease
Cytomegalovirus/immunology
Dideoxynucleosides/diagnostic use
Drug Therapy, Combination
HIV Infections/*drug therapy/immunology/virology
HIV Protease Inhibitors/therapeutic use
*Hiv-1
Humans
Nelfinavir/therapeutic use
Prospective Studies
RNA, Viral/blood
Reverse Transcriptase Inhibitors/therapeutic use
Saquinavir/therapeutic use
Simplexvirus/immunology
Sulfonamides/therapeutic use
T-Lymphocyte Subsets
Pubmed
Web of science
Create date
25/01/2008 15:13
Last modification date
20/08/2019 12:52